IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner
出版年份 2013 全文链接
标题
IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner
作者
关键词
Melanomas, Melanoma cells, Small interfering RNAs, Toll-like receptors, Apoptosis, Cancer treatment, RNA extraction, Gene expression
出版物
PLoS One
Volume 8, Issue 10, Pages e76159
出版商
Public Library of Science (PLoS)
发表日期
2013-10-15
DOI
10.1371/journal.pone.0076159
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- STAT3 Is Indispensable to IL-27-Mediated Cell Proliferation but Not to IL-27-Induced Th1 Differentiation and Suppression of Proinflammatory Cytokine Production
- (2014) T. Owaki et al. JOURNAL OF IMMUNOLOGY
- Antiproliferative Activity of IL-27 on Melanoma
- (2014) T. Yoshimoto et al. JOURNAL OF IMMUNOLOGY
- MDA5 Plays a Crucial Role in Enterovirus 71 RNA-Mediated IRF3 Activation
- (2013) Rei-Lin Kuo et al. PLoS One
- Interleukin-27 Inhibits the Growth of Pediatric Acute Myeloid Leukemia in NOD/SCID/Il2rg-/- Mice
- (2012) A. Zorzoli et al. CLINICAL CANCER RESEARCH
- Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer
- (2011) Touko Inao et al. BREAST CANCER RESEARCH AND TREATMENT
- Anticancer function of polyinosinic-polycytidylic acid
- (2011) Yu-sheng Cheng et al. CANCER BIOLOGY & THERAPY
- TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer
- (2011) B. Salaun et al. CANCER RESEARCH
- IL-27 Enhances LPS-Induced Proinflammatory Cytokine Production via Upregulation of TLR4 Expression and Signaling in Human Monocytes
- (2011) C. Guzzo et al. JOURNAL OF IMMUNOLOGY
- Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors
- (2011) Irma Airoldi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model
- (2011) S Canale et al. LEUKEMIA
- Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo
- (2011) C Cocco et al. LEUKEMIA
- TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis
- (2010) Manabu Taura et al. CANCER SCIENCE
- Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma
- (2010) C. Cocco et al. CLINICAL CANCER RESEARCH
- Interferon-induced TRAIL-independent cell death in DNase II−/− embryos
- (2010) Yusuke Kitahara et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages
- (2009) Tomozumi Imamichi et al. AIDS
- Interleukin-27 Activates Natural Killer Cells and Suppresses NK-Resistant Head and Neck Squamous Cell Carcinoma through Inducing Antibody-Dependent Cellular Cytotoxicity
- (2009) M. Matsui et al. CANCER RESEARCH
- Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow
- (2009) R. Salcedo et al. JOURNAL OF IMMUNOLOGY
- IL-27 Directly Restrains Lung Tumorigenicity by Suppressing Cyclooxygenase-2-Mediated Activities
- (2009) M.-Y. Ho et al. JOURNAL OF IMMUNOLOGY
- RNA recognition and signal transduction by RIG-I-like receptors
- (2008) Mitsutoshi Yoneyama et al. IMMUNOLOGICAL REVIEWS
- IL-27-Mediated Activation of Natural Killer Cells and Inflammation Produced Antitumour Effects for Human Oesophageal Carcinoma Cells
- (2008) L. Liu et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now